Article published on 2024-12-9

Harnessing Pharmacogenomics for Personalized Medicine: Tailoring Drug Therapy to Genetic Profiles

Pushpendra Kumar[1*], Ankit Goel[1], Pooja Malik[2], Surbhi Sirswal[3], Poonam Rishishwar[1], Sanjay Rishishwar[1]

[1]Maharaja Agrasen Himalayan Garhwal University, Pauri Garhwal, Uttarakhand, India, 246169
[2]School of Pharmaceutical Sciences, IFTM University Delhi Road Moradabad, 244102, India
[3]Siddhartha Institute of Pharmacy, Veer Madhav Singh Bhandari Uttarakhand Technical University, Dehradun, India

***Correspondence Author:**
Mr. Pushpendra Kumar,
Assistant Professor, Maharaja Agrasen Himalayan Garhwal University, Pokhra, Pauri Garhwal, Uttarakhand, India, 246169
Email ID: pusp92744@gmail.com

Chinese Journal of Applied Physiology, 2024: e20240035

Abstract This study means to investigate the capability of pharmacogenetics which can customize drug treatment through altered treatment of male genetic profiles. We finished hereditary profiling utilizing cutting edge sequencing (NGS) to figure out the key hereditary varieties that impact the medications metabolic adequacy and security. Patients were checked for a very long time to evaluate clinical results including ADRs and general wellness. Hereditary assessment uncovered variations in enormous qualities, for example, CYP2C9 CYP2D6 ABCB1 VKORC1 and SLCO1B1 which assume significant parts in drug digestion and transport. These hereditary markers are related with clinical realities to evaluate their effect on drug reactions and unfriendly impacts. The outcomes recommend that customized treatment dependent exclusively upon hereditary profiles could prompt better treatment results. For instance, patients with VKORC1 changes answer better to anticoagulants and drain less while patients with SLCO1B1 transformations have statin-incited myopathy which is more expensive and requires portion changes. This mirrors the useful effect of altered treatment on wellness results. Pharmacogenomics gives a useful asset to customized medication to tailor drug medicines dependent exclusively upon a person's genetic profile.

Keywords Pharmacogenomics; Personalized medicine; Genetic profiling; Drug metabolism; Clinical outcomes

Introduction

Pharmacogenomics the investigation of what hereditary variety means for drug reaction and digestion can possibly upset clinical preparation by empowering customized medication in light of a person's hereditary profile [1]. This field has transformed into a central area of investigation that beats any hindrance between innate pharmacology and not entirely set in stone to smooth out treatment practicality while restricting perilous outcomes. Normal drug uses one-size-fits-all medicine supporting procedures that much of the time contrast in calm responses and astonishing delayed

DOI: 10.62958/j.cjap.2024.035
www.cjap.ac.cn

Published by CJAP editorial office and Asian BioMed Innovation Press

consequences. Pharmacogenomics looks to address these requesting circumstances by describing what hereditary varieties mean for drug viability digestion and harmfulness in this way directing more extraordinary and individualized treatments systems [2].

These are generally found in qualities encoding drug-using compounds drug carriers and medication targets. For instance, polymorphisms in the CYP2D6 quality can cause changes in chemical action that influence the digestion of different medications including antidepressants beta-blockers and narcotics. Varieties in the VKORC1 quality might influence aversion to anticoagulant medications, for example, warfarin in this manner requiring custom fitted portion changes in view of the patient's hereditary profile [3]. The utilization of pharmacogenomics in clinical practice has significant ramifications for working on understanding consideration. By distinguishing hereditary markers related with drug reaction medical care suppliers can anticipate how patients will utilize and answer explicit medications. This information permits specialists to endorse the least difficult medications in the best portions expanding the adequacy of treatment and diminishing the chance of antagonistic results [4]. For instance, patients with specific hereditary changes might have to take lower portions of a medication to accomplish a restorative impact or might be processed diversely to keep away from devastating results. Genetic tumor profiling has led to treatments for most cancers. Targeted therapies primarily Herceptin for HER2-positive breast cancer and imatinib for BCR-ABL- positive persistent myeloid leukemia are treatments where genetic testing increases survival and inefficiency and provides new hope and better outcomes for patients. Improvements in next-generation genomic technologies (NGS) and genotyping systems support the integration of pharmacogenomics into clinical practice [5]. These technologies facilitate faster and more efficient genetic testing to increasingly integrate genetic information into routine medical decision-making [6]. The large-scale research projects of the Pharmacogenetics Research Network (PGRN) and the Clinical Pharmacogenetics Implementation Consortium (CPIC) provide normative recommendations and guidance for translating pharmacogenetic research into actionable scientific activities. Although the potential of pharmacogenomics is to be used the conditions are challenging such as the work of strong evidence linking genetic variants with clinical outcomes integration in electronic health records (EHRs) and education from health societies [7]. Multidisciplinary collaboration between clinical pharmacogenetics and policy makers is needed to create an infrastructure to promote recommendations to address these challenges and to educate the health profession about the clinical utility and ethical issues related to pharmacogenomic testing. Pharmacogenomics has been displayed to work on the adequacy and security of medication medicines fundamentally [8]. Individualized treatment systems can prompt better infectious prevention as proven by further developed pulse glucose levels and LDL-LDC control. Impacted person's fulfillment in sorting out customized medicines differed fundamentally.

Material and Methods

Chemicals

Chemical Name	Manufacturer	Grade	Quantity
DNA Extraction Kit (QIAamp)	Qiagen	Research Grade	As required
PCR Reagents	Invitrogen	Analytical	As required
Sequencing Reagents (TruSeq)	Illumina	Analytical	As required
Ethanol	Sigma-Aldrich	Reagent Grade	500 ml
Tris-EDTA Buffer	Thermo Fisher	Reagent Grade	500 ml

Apparatus

Apparatus Name	Manufacturer	Model	Quantity
NanoDrop Spectrophotometer	Thermo Fisher	NanoDrop 2000	1
Next-Generation Sequencer	Illumina	HiSeq 2500	1
PCR Machine	Bio-Rad	T100	1
Centrifuge	Eppendorf	5424	2
DNA Extraction Unit	Qiagen	QIAcube	1
Bioinformatics Workstation	Dell	Precision 7920	2
Computer for Data Analysis	HP	EliteBook	3



Figure 1: Next-generation sequencing (NGS) Machine

Patient Selection

Patients were recruited from the outpatient clinics of the health centre. Inclusion criteria included individuals aged 18 to 65 years with chronic disease including cardiovascular disease diabetes or cancer taking chronic medication and being able to provide informed consent for genetic testing and information sharing. including the elderly.

Genetic Profiling

Blood samples (5 mL) were collected from each player for genetic analysis. Genomic DNA can be extracted using the QIAamp DNA Blood Mini Kit (Qiagen) according to the manufacturer's instructions [9]. DNA samples will be quantified and purity evaluated using a NanoDrop spectrophotometer. Genetic analysis will be conducted using next generation technology on the Illumina (NGS) platform that specializes in the study of pharmacogenomic markers known to be important for drug metabolism efficiency and toxicity [10]. Sequencing libraries can be prepared using the TruSeq DNA PCR-Free Library Prep Kit (Illumina) and sequenced to measure at least 30-fold coverage to ensure reliable variant identification. Quality control included alignment using FastQC and BWA to assess read coverage strength and variant accuracy.

Data Collection

Collection of comprehensive medical data including demographic facts (age breed) targeted clinical notes and current medications, adverse drug reactions. To check the safety and efficacy of drug, clinical results can be examined in 12 months period with periodic visits every three months.



Figure 2: Next-generation sequencing (NGS)

Integration and Analysis

Genetic records can be analyzed to find variants associated with drug response. Sequence data can be aligned to the human reference genome (GRCh38) using BWA-MEM [11]. Variant calling can be performed using the Genome Analysis Toolkit (GATK) and variants can be annotated with useful information from databases including dbSNP ClinVar and PharmGKB. This analysis will identify single nucleotide polymorphisms (SNPs) and insertions/deletions (INDELS) in genes encoding drug-metabolizing enzymes (e.g. CYP450 relatives) drug transporters (e.g. ABC transporters) and drug targets (e.g. receptors) [12]. The integration of genetic and clinical data will include identified genetic variants associated with response to prescribed medications. Correlation evaluation will be descriptive in nature as patterns and trends are observed without formal statistical testing. Case studies of male or female victims may be presented to demonstrate unique examples where genetic profiles significantly influence the outcome of drug therapy.

Ethical Considerations

This study met standards for research involving human subjects. Institutional Review Board (IRB) approval was obtained and written informed consent was obtained from all participants. By analyzing statistical data and storing it securely genetic and clinical facts can be kept confidential.

Inclusion and Exclusion Criteria

The inclusion criteria were designed to select a group of patients who may benefit from pharmacological intervention. Adults ages 18 to 65 who require medication have chronic medical conditions and wish to undergo genetic testing may be included. Patients must be able to provide informed consent and comply with the screening protocol. Exclusion criteria were designed to minimize confounding factors and ensure patient protection. Individuals with serious medical conditions pregnant and nursing women individuals with known genetic disorders not related to drug metabolism and individuals unable to provide informed consent may be excluded. Patients taking experimental or study pills were also excluded.

Results

This clinical trial aims to apply drug therapy to personalized medicine by customizing drug treatment based on genetic profiles. A total of 200

patients suffering from chronic diseases including cardiovascular disease diabetes and certain cancers were enrolled. Participants were genotyped and followed for 12 months [13]. The following sections describe various outcomes including genetic variants drug response patterns adverse drug reactions (ADRs) and clinical outcomes.

Genetic Variant Identification

Genotyping has resulted in numerous publications on genes related to metabolism transport and drug targets. The main findings are summarized in Table 1.

These genetic variants generally significantly affect the metabolism and effectiveness of pharmaceutical drugs. For example, variants in the CYP2C9 and CYP2D6 genes known to metabolize a variety of drugs were identified in a significant proportion of the cohort suggesting a potential need for dose adjustment or treatment modification [14].

Drug Response Patterns

Integrating genetic data with scientific findings has yielded clear patterns of drug response driven by genetic variation. Response to statin anticoagulants and antihypertensive medications varied greatly between participants depending on their genetic profiles.

Participants with the VKORC1 rs9923231 variant showed a higher response rate to anticoagulants with fewer ADRs than participants without the variant [15]. Conversely those with the SLCO1B1 rs4149056 variant had reduced statin clearance leading to increased

Table 1: Key Genetic Variants Identified

Gene	Variant	Allele Frequency	Function
CYP2C9	rs1057910	12%	Reduced enzyme activity
CYP2D6	rs3892097	8%	Poor metabolizer phenotype
ABCB1	rs1045642	15%	Altered drug transport
VKORC1	rs9923231	18%	Altered warfarin sensitivity
SLCO1B1	rs4149056	20%	Reduced statin clearance



muscle-related side effects.

The significance of hereditary profiling in foreseeing drug viability and wellbeing were stressed by these discoveries.

Adverse Drug Reactions (ADRs)

ADRs were painstakingly recorded and broke down to evaluate the effect of hereditary variations on drug security. Table 3 sums up the occurrence of ADRs by drug class and genetic type.

The frequency of secondary effects is essentially higher in people with explicit hereditary variations. For instance, people with the SLCO1B1 variation had more statin-instigated myopathy while people with the ABCB1 variation had a higher occurrence of incidental effects related with anticancer specialists [16]. These discoveries feature the requirement for individualized drug treatment to limit incidental effects and work on persistent security.

Clinical Outcomes

Clinical results were assessed to decide the general adequacy of the individualized medication in light of pharmacokinetic information. Patients were monitored for medication adherence and average health status for improvement in disease markers.

Participants who received personalized treatment based on their genetic profile showed significantly improved clinical outcomes compared to those who received conventional treatment [17]. In hypertensive patient's blood pressure control increased from 55% to 70% and in diabetic patients HbA1c reduction increased from 60% to 80%. Reductions in LDL cholesterol 65% to 75% and tumor response rates in cancer patients 50% to 65% have been observed in statin-treated patients. Patient satisfaction was higher in personalized care settings by 85% than in standard care settings by 70%.

Table 2: Drug Response by Genetic Variant

Drug Class	Genetic Variant	Response Rate	Adverse Reactions (%)
Anticoagulants	VKORCI (rs9923231)	70%	10%
Stains	SLCO1B1 (rs4149056)	65%	15%
Beta-blockers	CYP2D6 (rs3892097)	60%	12%
Antidiabetics	CYP2C9 (rs1057910)	75%	8%
Anticancer Agents	ABCB1 (rs1045642)	55%	18%

Table 3: Incidence of ADRs by Drug Class and Genetic Variant

Drug Class	Genetic Variant	Incidence of ADRs (%)	Common ADRs
Anticoagulants	VKORC1 (rs9923231)	10%	Bleeding, bruising
Statins	SLCO1B1 (rs4149056)	15%	Myopathy, liver dysfunction
Beta-blockers	CYP2D6 (rs3892097)	12%	Fatigue, dizziness
Antidiabetics	CYP2C9 (rs1057910)	8%	Hypoglycemia, gastrointestinal issues
Anticancer agents	ABCB1 (rs1045642)	18%	Nausea, neuropathy

Table 4: Clinical Outcomes by Genetic Profiling

Clinical Outcome	Standard Therapy	Personalized Therapy
Blood Pressure Control (Hypertension)	55%	70%
HbA1c Reduction (Diabetes)	60%	80%
LDL Cholesterol Reduction (Statins)	65%	75%
Tumor Response Rate (Cancer)	50%	65%
Patient Satisfaction	70%	85%



Case Studies

Several case studies highlight the clear benefits of personalized medicine. A patient with the CYP2C9 rs1057910 variant who experienced frequent hypoglycemia while taking a popular antidiabetic drug was switched to an alternative drug with a lower risk of hypoglycemia [18]. This exchange eventually leads to high blood sugar levels and a change in first-class life. Another patient with the ABCB1 rs1045642 variant demonstrated a significant reduction in signs and symptoms of neuropathy when the dose of anticancer drugs was adjusted according to their genetic profile [19].

Discussion

Our discoveries with respect to the utilization of pharmacogenomics to customized medication show the significant effect of hereditary profiling on the adequacy of medication treatment [20]. The ID of key hereditary variations including the CYP2C9 CYP2D6 ABCB1 VKORC1 and SLCO1B1 qualities has given significant understanding into what hereditary variations mean for the adequacy and wellbeing of medication digestion [21]. For instance, the VKORC1 variation rs9923231 fundamentally impacted anticoagulant reactions bringing about diminished antagonistic medication responses (ADRs) and further developed treatment results contrasted with the nonmutated variation [22]. Essentially, the SLCO1B1 variation rs4149056 is related with an expanded frequency of statin-instigated myopathy featuring the significance of hereditary testing prior to recommending statins to decrease facial aftereffects [23]. The mix of hereditary data and logical disclosures has affirmed that customized medicines are principally founded on hereditary profiles [24]. Patients who received personalized care had higher response rates and fewer side effects across drug categories compared to over-the-counter anticoagulants statins beta blockers antidiabetic agents and anticancer drugs [25]. For example, personalized therapy increased her



Figure 3: Personalised medicine

blood pressure from 55% to 70% in a hypertensive patient and decreased her HbA1c from 60% to 80% in a diabetic patient [26]. These improvements highlight the power of pharmacology to translate drug efficacy and safety into better clinical outcomes.The real benefits of personalized medicine through case studies. Impacted people with the CYP2C9 rs1057910 variation had productive stable blood glucose levels and worked on personal satisfaction subsequent to changing to antidiabetic drugs with a diminished risk of hypoglycemia [27]. Others with the ABCB1 rs1045642 variation showed a significant decrease in neurological signs and side effects after portion change of anticancer medications in view of their hereditary profile. These cases feature this present reality utilization of pharmacogenomics in working on quiet consideration [28]. The high commonness of ADRs in patients with specific variants of the quality stresses the requirement for hereditary testing prior to beginning a positive medication. By recognizing patients in danger of unfriendly responses medical care associations can change drug determination and measurements to lessen the probability of unfavorable responses. This technique now works on quiet security as well as treatment consistence and fulfillment.

Conclusion

Pharmacogenomics may incredibly work on customized medication by fitting medications to hereditary profiles. Upgrading drug viability can assist with recognizing key hereditary variations to lessen antagonistic responses and work on clinical results in numerous persistent sicknesses [29, 31]. Customized restoration has brought about better persistent fulfillment and features the significance of coordinating hereditary testing into clinical practice. Patient fulfillment rates were fundamentally better at the assigned clinical office which decidedly affected praiseworthy wellbeing and prosperity. The capacity to fit medicines to individual hereditary profiles gives patients trust in the adequacy and security of their drugs [30]. This expanded fulfillment likewise upholds the combination of pharmacogenomics into routine clinical practice. These study serious areas of strength for gives that pharmacogenomics can altogether

work on customized medication by fitting medication treatment in view of hereditary profiles.

Conflict of interest

The writers attest that there is not a conflict between their interests in the article's content.

References

1. Cecchin E, Stocco G. Pharmacogenomics and personalized medicine. Genes. 2020 Jun 22;11(6):679.
2. Singh, D.B., 2020. The impact of pharmacogenomics in personalized medicine. Current Applications of Pharmaceutical Biotechnology, 369-394.
3. Jeibouei S, Akbari ME, KAlbasi A, Aref AR, Ajoudanian M, Rezvani A, Zali H. Personalized medicine in breast cancer: Pharmacogenomics approaches. Pharmacogenomics and Personalized medicine. 2019 May 27:59-73.
4. Hassan r, Allali I, Agamah FE, ElsheikhSS, Thomford NE, Dandara C, Chimusa ER. Drug response in association with pharmacogenomics and pharmacomicrobiomics towards a better personalized medicine. Briefing in bioinformatics. 2021 July;22(4): bbaa292.
5. Venkatachalapathy P, Padhilahouse S, Sellappan M, Subramanian T, Kurian SJ, Miraj SS, Rao M, Raut AA, Kanwar RK, Singh J, Khadanga S. Pharmacogenomics and personalized medicine in type 2 diabetes mellitus: potential implications for clinical practice. Pharmacogenomics and Personalized Medicine. 2021 Nov 13:1441-55.
6. Núñez-Torres R, González-Neira A. Pharmacogenetics and personalized medicine. In Clinical DNA Variant Interpretation 2021 Jan 1 (pp. 193-219). Academic Press.
7. Balogum OD, Ayo-Farai O, Ogundairo O, Maduka CP, Okongwu CC, Babarinde Sodamade OT. The role of pharmacist in personalized medicine: A review of integrating pharmacogenomics into clinical practice. International Medical Science Research Journal 2024 Jan 8;4(1):19-36.
8. Abad- Santos F, Alino SF, Borobia AM, Garcia-Martin E, Gasso P, Maronas O, Agundez JA.Developments in pharmacogenetics, pharmacogenomics, and personalized medicine. Pharmacological Research. 2024 Feb 1;200:107061
9. Siamoglou S, Koromina M, Moy FM, Mitropoulou C, Patrinos GP, Vasileiou K. What do students in pharmacy and medicine think about pharmacogenomics and personalized medicine education? Awareness, attitudes, and perceptions in Malaysian Health Sciences. OMICS: A Journal of Integrative Biology. 2021 Jan 1;25(1):52-9.
10. Primorac D, Bach-Rojecky L, Vadunec D, Juginovic A, Zunic K, Matisic V, Skelin A, Arsov B, Boban L, Erceg D, Ivkosic IE. Pharmacogenomics at the center of precision medicine challenges and perspective in the era of Big Data Pharmacogenomics: 2020 Jan1;21(2):141-56.
11. Tafazoli A, Wawrusiewicz-Kurylonek N, Posmyk R, Miltyk W. Pharmacogenomics, how to deal with different types of variants in next generation sequencing data in the personalized medicine area. Journal of Clinical Medicine. 2020 Dec 24;10(1):34.
12. Goricar K, Dolzan V, Lenassi M. Extracellular vesicles. A novel tool facilitating personalized medicine and pharmacogenomics in oncology. Frontiers in pharmacology. 2021 April 30;12:671298.
13. Singh P. Pharmacogenomics advances customizing drug therapies for individual patients. Journal of Advanced Research on pharmaceutical Sciences and Pharmacology Intervention. 2023 July 14;6(1):21-7.
14. Schwarz UI, Gulilat M, Kim RB. The role of next generation sequencing in pharmacogenetics and pharmacogenomics. Cold spring Harbor Perspective in Medicine. 2019 Feb 1;9(2): a033027
15. Van der Lee M, Kriek M, Guchelear HJ, Swen JJ. Technologies for pharmacogenomics. A review. Genes. 2020 Dec 4;11(2):1456
16. Giannopoulou E, Katsila T, Mitropoulou C, Tsermpini EE, Patrinos GP. Integrating next-generation sequencing in the clinical pharmacogenomics workflow. Frontiers in pharmacology. 2019 Apr 5;10:384.
17. Russell LE, Zhou Y, Almousa AA, Sodhi JK, Nwabufo CK, Lauschke VM. Pharmacogenomics in the era of next generation sequencing–from byte to bedside. Drug Metabolism Reviews. 2021 Apr 3;53(2):253-78.
18. Morganti S, Tarantino P, Ferraro E, D'Amico P, Duso BA, Curigliano G. Next generation sequencing (NGS): a revolutionary technology in pharmacogenomics and personalized medicine in cancer. Translational research and onco-omics applications in the era of cancer personal genomics. 2019:9-30.
19. Enko D, Michaelis S, Schneider C, Schaflinger E, Baranyi A, Schnedl WJ, Muller DJ. The Use of Next-Generation Sequencing in Pharmacogenomics. Clinical Laboratory. 2023 Aug 1;69(8).
20. Tafazoli A, Guchelaar HJ, Miltyk W, Kretowski AJ, Swen JJ. Applying next-generation sequencing platforms for pharmacogenomic testing in clinical practice. Frontiers in Pharmacology. 2021 Aug 25;12:693453.
21. Taylor C, Crosby I, Yip V, Maguire P, Pirmohamed M, Turner RM. A Review of the Important Role of CYP2D6 in Pharmacogenomics. Genes. 2020 Oct 30;11(11):1295.
22. Balestrini S, Sisodiya SM. Pharmacogenomics in epilepsy. Neuroscience letters. 2018 Feb 22;667:27-39.
23. Zhou Y, Lauschke VM. Next-generation sequencing in pharmacogenomics–fit for clinical decision support. Expert Review of Clinical Pharmacology. 2024 Mar 3;17(3):213-23.
24. Pirmohamed M. Pharmacogenomics: current status and future perspectives. Nature Reviews Genetics. 2023 Jun;24(6):350-62.
25. Zhou Y, Koutsilieri S, Eliasson E, Lauschke VM. A paradigm shift in pharmacogenomics: From candidate polymorphisms to comprehensive sequencing. Basic & Clinical Pharmacology & Toxicology. 2022 Dec;131(6):452-64.

26. Wang L, Weinshilboum R. Pharmacogenomics in practice. Clinical pharmacology and therapeutics. 2019 Nov;106(5):936.
27. Orrico KB. Basic concepts in genetics and pharmacogenomics for pharmacists. Drug Target Insights. 2019 Nov;13: 1177392819886875.
28. Caspar SM, Schneider T, Stoll P, Meienberg J, Matyas G. Potential of whole-genome sequencing-based pharmacogenetic profiling. Pharmacogenomics. 2021 Feb 1;22(3):177-90.
29. Siamoglou S, Koromina M, Hishinuma E, Yamazaki S, Tsermpini EE, Kordou Z, Fukunaga K, Chantratita W, Zhou Y, Lauschke VM, Mushiroda T. Identification and functional validation of novel pharmacogenomic variants using a next-generation sequencing-based approach for clinical pharmacogenomics. Pharmacological Research. 2022 Feb 1;176:106087.
30. Van der Lee M, Rowell WJ, Menafra R, Guchelaar HJ, Swen JJ, Anvar SY. Application of long-read sequencing to elucidate complex pharmacogenomic regions: a proof of principle. The pharmacogenomics journal. 2022 Feb;22(1):75-81.
31. Dash B, Murshidha Shireen, Pushpendra, Kumar S, Goel A, Semwal P, Rani R. A Comprehensive Review: Pharmacogenomics and Personalized Medicine Customizing Drug Therapy Based on Individual Genetics Profiles. Chinese Journal of Applied Physiology. 2024 Jul 9:e202400.